The Hidden Threat of Estrogen Receptor-Positive Breast Cancer Estrogen receptor-positive (ER+) breast cancer is the most prevalent form of the…
Read More
Breast cancers that disseminate to bone marrow acquire aggressive phenotypes through CX43-related tumor-stroma tunnels
In a breakthrough study published in the Journal of Clinical Investigation, researchers from the University of Michigan and the University…
Read More
Breast cancers that disseminate to bone marrow acquire aggressive phenotypes through CX43-related tumor-stroma tunnels
Researchers from the University of Michigan and the University of California San Diego have published a groundbreaking study identifying the…
Read More
Breast cancers that disseminate to bone marrow acquire aggressive phenotypes through CX43-related tumor-stroma tunnels.
This fundamental discovery, detailed in a collaborative study by researchers from the University of Michigan and the University of California…
Read More
How breast cancer cells survive in bone marrow after remission
The study, published in the Journal of Clinical Investigation, identifies a sophisticated "smuggling" operation between cancer cells and the bone…
Read More
Breast cancers that disseminate to bone marrow acquire aggressive phenotypes through CX43-related tumor-stroma tunnels
The persistence of estrogen receptor-positive (ER+) breast cancer remains one of the most formidable challenges in modern oncology, as patients…
Read More
Telomir Pharmaceuticals Submits Investigational New Drug Application for Telomir-1 to FDA for Advanced Triple-Negative Breast Cancer
Telomir Pharmaceuticals has taken a significant stride in its mission to combat advanced and metastatic triple-negative breast cancer (TNBC) by…
Read More
Breast cancers that disseminate to bone marrow acquire aggressive phenotypes through CX43-related tumor-stroma tunnels
The phenomenon of cancer recurrence remains one of the most significant challenges in modern oncology, particularly in the context of…
Read More
Novartis Acquires Promising Breast Cancer Drug SNV4818 from Synnovation Therapeutics for Up to $3 Billion
Novartis has announced a significant strategic move to bolster its oncology pipeline with the acquisition of SNV4818, an investigational oral…
Read MoreYOU MAY HAVE MISSED
